Analyst ahead of Genmab report: Focus will be on Darzalex prognosis

Genmab’s 2022 guidance will take center stage when the company presents its full-year financial report on Wednesday.

Photo: Joost Melis / Genmab / PR

Some of the excitement has been taken out of Genmab’s full-year financial report, which will be publicized on Wednesday. The company’s partner Johnson & Johnson has already published figures for Genmab’s biggest source of revenue, cancer drug Darzalex.

Darzalex fourth quarter sales have been reported at USD 1.645bn compared to the estimated USD 1.636bn based on analysts’ predictions, which were collected by Bloomberg News.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs